TABLE 1.
Baseline Characteristics by Treatment Group
| Variable | Total (n = 57) | No-AT (n = 38) | AT (n = 19) | P value |
|---|---|---|---|---|
| Age, y, median (IQR) | 66 (58-76) | 66 (58-76) | 70 (58-76) | .89 |
| Female sex, n (%) | 12 (21.1) | 6 (15.8) | 6 (31.6) | .19 |
| Bilateral lesions, n (%) | 9 (15.8) | 5 (13.2) | 4 (21.1) | .46 |
| Evacuation, n (%) | ||||
| Burr holes | 23 (40.4) | 18 (47.4) | 5 (26.3) | .16 |
| Craniotomy | 11 (19.3) | 6 (15.8) | 5 (26.3) | .48 |
| Embolization material, n (%) | ||||
| Particles | 42 (73.7) | 29 (76.3) | 13 (68.4) | .54 |
| Coils | 44 (77.2) | 31 (81.6) | 13 (68.4) | .32 |
| Onyx | 13 (22.8) | 7 (18.4) | 6 (31.6) | .32 |
| Pre-antiplatelet agents, n (%) | 15 (26.3) | 7 (18.4) | 8 (42.1) | .11 |
| Aspirin | 15 (26.3) | 7 (18.4) | 8 (42.1) | .11 |
| Clopidogrel | 2 (3.5) | 1 (2.6) | 1 (5.3) | 1 |
| Pre-anticoagulants, n (%) | 13 (22.8) | 2 (5.3) | 11 (57.9) | <.001 |
| Heparin | 3 (5.3) | 0 (0.0) | 3 (15.8) | .033 |
| Warfarin | 9 (15.8) | 1 (2.6) | 8 (42.1) | <.001 |
| DOAC | 3 (5.3) | 1 (2.6) | 2 (10.5) | .26 |
| Post-antiplatelet agents, n (%) | 8 (14.0) | 8 (42.1) | ||
| Aspirin | 8 (14.0) | 8 (42.1) | ||
| Clopidogrel | 1 (1.8) | 1 (5.3) | ||
| Postoperative start, d, median (IQR) | 2 (.5-2.5) | 2 (.5-2.5) | ||
| Post-anticoagulant, n (%) | 14 (24.6) | 14 (73.7) | ||
| Heparina | 10 (17.5) | 10 (52.6) | ||
| PTT, s, median (range) | 59.6 (24-175) | |||
| Warfarina | 6 (10.5) | 6 (31.6) | ||
| INR, median (range) | 2.0 (1.5-2.8) | |||
| DOAC | 1 (1.8) | 1 (5.3) | ||
| Postoperative start, d, median (IQR) | 1 (0-2) | 1 (0-2) |
ATs, antithrombotics; DOAC, direct oral anticoagulant; INR, international normalized ratio; PTT, partial thromboplastin time.
a
Four cases were on heparin bridge to warfarin. Sample size refers to per patient and not per subdural hematoma.
Data were analyzed by the Student t test for continuous variables or the Fisher exact test for categorical variables.